1. In Vivo
  2. >>Deal-Making

Deals Shaping The Medical Industry, December 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2015.

Vigilant Biosciences Inc. signed three new multi-year distribution agreements for marketing of its CE-marked oral cancer diagnostic, the OncAlert oral cancer system. Dentamed Ltd. gets rights in Slovakia and the Czech Republic; SIRAM Ltd. will sell the test in Israel; and Diamedica Ltd. will sell it in Estonia, Latvia, and Lithuania. (Nov.)

The risk assessment system consists of OncAlert oral cancer rapid point-of-care test, an oral rinse that, when expelled into a cup and tested with a special device, can detect certain protein biomarkers indicative of early-stage oral cancer risk even before visual or physical symptoms appear. The companies will also sell the OncAlert oral cancer CD44+ total protein lab test, an expelled oral rinse that can stratify a patient’s level of risk into specific categories. Vigilant's new partners will begin selling the system in the licensed territories during the first quarter of 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.